IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
Comments Off on IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
May 14, 2026
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchClinical TrialsAnxietySleepCBDSafetyIndustry Clinical Summary IGC Pharma has expanded its Phase 2 CALMA trial by…
Tirzepatide vs Retatrutide: Efficacy Safety Comparison
GLP-1 Clinical Relevance #49Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialPhase 2 StudyObesityTirzepatideEndocrinologyAdults with ObesityWeight…
GLP-1 Receptor Agonists: Clinical Evidence and Outcomes
Comments Off on GLP-1 Receptor Agonists: Clinical Evidence and Outcomes
May 10, 2026
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialPhase 2 StudyIntracranial HypertensionExenatideNeurologyWomen with…